Financials

News Discussions Technicals Forecast Seasonals

4147 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

TaiMed Biologics, Inc. engages in the new drug development for human immunodeficiency virus (HIV). Its products include: (1) TMB-355 for the latter part of acquired immune deficiency syndrome (AIDS) medication. (2) TMB-360/365 for anti-AIDS virus. (3) TMB-607 Protease inhibitors for the anti-AIDS virus. The company was founded by David Ho, LanBo Chen and Ing-Wen Tsai on September 4, 2007 and is headquartered in Taipei, Taiwan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

4147 does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company